Lymphocyte-to-monocyte ratio associated with severe post-stenotic aortic dilation in a case–control study

Shanghao Chen1,2†, Zezhong Wu1,2†, Yan Yun3†, Hechen Shen1,2, Diming Zhao1,2, Yanwu Liu1,2, Chengwei Zou1,2, Haizhou Zhang1,2, Zhengjun Wang1,2 and Xiaochun Ma1,2*

Abstract

Background: Calcific aortic valve stenosis (CAVS) represents a serious health threat to elderly patients. Post-stenotic aortic dilation, a common feature in CAVS patients, might progress into aneurysm and even dissection, potential consequences of CAVS, and predicts a poor prognosis. This study sought to investigate the association of lymphocyte-to-monocyte ratio (LMR), an inflammatory biomarker, with severe post-stenotic aortic dilation in a case–control study in Chinese population.

Materials and methods: 208 consecutive patients with CAVS were recruited retrospectively in a case–control study in Chinese population, from July 1, 2015 to June 31, 2018. LMR was statistically analyzed using the ROC curve and binary logistic regression analyses for its prognostic value in severe post-stenotic aortic dilation.

Results: LMR was significantly reduced in patients with severe post-stenotic aortic dilation (2.72 vs. 3.53, \( p = 0.002 < 0.05 \)) compared to patients without severe post-stenotic aortic dilation. There was an inverse correlation observed between the maximal diameter of ascending aorta and LMR in the overall patients (\( r = -0.217, \ p = 0.002 < 0.05 \)). For post-stenotic aortic dilation, the prevalence of high-LMR group was statistically lower than that of low-LMR group (19.7% vs. 43.9%, \( p < 0.001 \)). The maximal diameter of ascending aorta was significantly reduced in the high-LMR group (4.35 vs. 4.76, \( p = 0.003 < 0.05 \)) compared to low-LMR group. Additionally, LMR was identified in the multivariate analysis independently associated with severe post-stenotic aortic dilation (AUC 0.743, 95% CI: [0.573–0.964], \( p = 0.025 \)).

Conclusions: This study provided the evidence of an inverse correlation between severe post-stenotic aortic dilation and LMR. LMR is potentially independently associated with severe post-stenotic aortic dilation.

Keywords: Lymphocyte-to-monocyte ratio, Post-stenotic aortic dilation, Association

Introduction

Calcific aortic valve stenosis (CAVS) is the most prevailing heart valve disorder and affects nearly 1.7% in the population > 65 years old in developed countries [1]. As the population ages, the prevalence has also rapidly increased in developing countries [2]. Post-stenotic aortic dilation is common in patients with CAVS and might advance into aortic aneurysm and dissection [3, 4]. Thus, post-stenotic aortic dilation warrants regular medical
monitoring to prevent dissection or rupture. In the management of patients with CAVS, it is necessary to decipher additional risk for post-stenotic aortic dilation, in an attempt to optimize the assessment of dilation progression, and clinical decision-making of a combined aorta replacement surgery. However, current data are scarce regarding the determinants and predictors of post-stenotic aortic dilation.

The pathophysiology of post-stenotic aortic dilation remains largely undetermined. Current evidence supported that this entity of aortic dilation might be due to the unfavorable hemodynamic conditions downstream of stenotic valves, or due to the valve anatomy (BAV and tricuspid aortic valve [TAV]) as well as the intrinsic pathology of aorta [5]. Given a pivotal role of inflammation widely recognized in the pathogenesis of CAVS, inflammation might also be linked with the development of post-stenotic aortic dilation. Of note, several inflammatory diseases as well as inflammatory biomarkers have been correlated with aortic dilation, suggesting the effects of systemic and localized inflammation on the pathophysiology [6–9].

Lymphocyte-to-monocyte ratio (LMR) is an inflammatory biomarker calculated from peripheral blood count of lymphocytes and monocyte/macrophages. It has recently been associated with severity of coronary artery disease and prognosis following coronary artery bypass graft and percutaneous coronary intervention [10–12]. Besides, LMR has also been linked with the severity of rheumatic mitral valve stenosis, death prediction in heart failure and survival after endovascular repair of abdominal aortic aneurysms [13–15]. Here we hypothesized that LMR might function as a predictive indicator of severe post-stenotic aortic dilation and aimed to confirm this hypothesis in a case–control study in Chinese population.

Material and methods

Participants and study design

This study was a single-center retrospective case–control study. It was approved by the Ethics Committee of Shandong Provincial Hospital affiliated to Shandong First Medical University and Shandong University and the approval code for this study is NSFC2018-002. Due to its retrospective design, the written informed consents had to be waived. The study was performed in accordance with the Good Clinical Practice (GCP) and principles of the Declaration of Helsinki [16]. 208 patients were consecutively included in the study from the hospital above-mentioned, from July 1, 2015 to June 31, 2018. The time interval of this study was based on its funding which spanned roughly a similar period. All the included patients met the following criteria: (1) older than 18 years; (2) having a clear diagnosis of CAVS based on the criteria by the American College of Cardiology (ACC) and the American Heart Association (AHA). The subjects were excluded due to the following exclusion criteria: (1) the presence of rheumatic aortic valve stenosis or insufficiency, severe stenosis or insufficiency of mitral or tricuspid valves, endocarditis, coronary artery disease, atrial fibrillation, autoimmune diseases, malignancies and renal, hepatic or hematologic disorders; (2) suspicious findings of genetic tests or physical exam and family history suggesting a connective tissue disease; (3) whose related data were not sufficient. All conditions have been excluded that possibly affect these cell lines, especially the lymphocytes and monocytes. HIV infection has been excluded because all patients have been tested negative and corticosteroid administration has been similar between the two groups (Table 1). Although lymphopenia due to viral infections was hard to be excluded, no record of possible symptoms or administration of anti-viral drugs has been found. The recruited patients underwent a comprehensive evaluation of transthoracic echocardiography (TTE) and aortic CT angiography (CTA). The blood counts were measured and calculated for LMR before the aortic CTA or TTE was performed. Full blood counts were routinely collected for calculating LMR by dividing the number of lymphocytes by the number of monocytes.

The definition of severe post-stenotic aortic dilation

The maximal diameter of ascending aorta was measured by aortic CTA and severe post-stenotic aortic dilation was defined as the maximal diameter equal to or greater than 50 mm [17].

The calculation of LMR and grouping by LMR

LMR was measured according to the lymphocyte and monocyte counts in the blood routine test. The cut-off LMR was decided by the diagnostic test as described below. The included patients were accordingly grouped as the low-LMR group (with their LMR values less than the cut-off values) and high-LMR group (with their LMR values greater than the cut-off values).

Statistical analysis

All statistical analysis was performed using the software SPSS Statistics 25.0. The continuous variables were present in the form of mean ± standard deviation (SD) if the data conforms to normal distribution, or expressed as median (quartile deviation) if the data inconsistent with the normal distribution. The categorical variables were shown as frequencies (n) with percentages (%). For analyzing the continuous variables, the Student...
t-test was used when the normal distribution was conformed. Otherwise, the non-parametric Mann–Whitney U test was applied if a skewed distribution was met. The Chi-square or Fisher’s exact test was carried out for analyzing the categorical variables. The cut-off LMR was determined by the diagnostic tests using the receiver operating curve (ROC). The binary logistic regression analysis was employed for the univariate and multivariable analyses. When the efforts were made to construct a multivariable predictive model, all candidate variables derived from the univariable analysis (with a \( p \) value less than 0.1) as well as those possible predictive variables were selected. In logistic regression model, variables with \( p < 0.10 \) in the univariate model were entered into a multivariable predictive model and Forward: LR was undertaken with the probability of entry and removal as 0.10 and 0.20, respectively. A two-sided \( p \) value less than 0.05 was considered statistically significant.

### Results

**Characteristics of patients**

**Inclusion of patients**

From July 1, 2015 to June 31, 2018, 243 patients were recruited in sequence. 23 subjects were excluded because of the presence of rheumatic aortic valve stenosis (11 cases), severe stenosis or insufficiency of other valves (15 cases), endocarditis (2 cases), coronary artery disease (8 cases), atrial fibrillation (12 cases), autoimmune disease (2 cases), malignancies and renal, hepatic or hematologic disorders (3 cases); 12 patients excluded whose clinical data were insufficient (Fig. 1).

**Detailed information of patients**

For the patients with severe post-stenotic aortic dilatation, 71.9% were male patients with a median age of 60.0 (11.0) years. 54.4% of patients were cigarette smokers, 33.3% had hypertension and 5.3% were with type 2 diabetes. 59.6% of patients had tricuspid aortic valve. The median LVEF was 57.0 (7.5). For the patients without severe

### Table 1  Clinical Characteristics of Patients with post-stenotic aortic dilatation and control group

|                         | Post-stenotic aortic dilatation | Control group | \( p \) value |
|-------------------------|---------------------------------|---------------|--------------|
| Patient population (n)  | 57                              | 151           |              |
| Demographic data        |                                 |               |              |
| Age (years)             | 60.0 (11.0)                     | 60.0 (12.0)   | 0.909        |
| Sex, male (n)           | 41 (71.9%)                      | 94 (62.3%)    | 0.174        |
| Medical history         |                                 |               |              |
| Hypertension (n)        | 19 (33.3%)                      | 56 (37.1%)    | 0.638        |
| Smoking (n)             | 31 (54.4%)                      | 63 (41.7%)    | 0.094        |
| Diabetes (n)            | 3 (5.3%)                        | 15 (9.9%)     | 0.435        |
| Tricuspid aortic valve (n) | 34 (59.6%)                  | 79 (52.3%)    | 0.321        |
| Chronic use of glucocorticoid (n) | 21 (36.8%)         | 62 (41.1%)    | 0.636        |
| Baseline echocardiography |                               |               |              |
| LVEDD (cm)              | 6.02 (1.74)                     | 5.45 (1.49)   | 0.011        |
| LVEF (%)                | 57 (7.5)                       | 60 (7)        | 0.006        |
| Laboratory tests        |                                 |               |              |
| Leukocyte (10^9/L)      | 6.11 (2.06)                     | 5.89 (1.96)   | 0.405        |
| Neutrophil (10^9/L)     | 3.48 (1.54)                     | 3.49 (1.51)   | 0.896        |
| Platelet (10^9/L)       | 178 (75.5)                      | 195.5 (71.5)  | 0.183        |
| Monocyte (10^9/L)       | 0.59 (0.37)                     | 0.50 (0.24)   | 0.006        |
| Lymphocyte (10^9/L)     | 1.74 (0.68)                     | 1.84 (0.68)   | 0.675        |
| LMR                     | 2.72 (1.62)                     | 3.53 (1.75)   | 0.002        |
| LDL-C (mmol/L)          | 2.78 (1.15)                     | 2.80 (1.19)   | 0.843        |
| CRP (mg/L)              | 0.93 (0.91)                     | 0.91 (1.62)   | 0.388        |
| MPV (fl)                | 10.60 (1.15)                    | 10.90 (1.25)  | 0.329        |

The categorical variables in the table are presented by the number of cases (with percentage) and the continuous variables are expressed by the median (with interquartile range) or mean (with standard deviation).

\( p \) values were the results of unpaired t-test or Mann–Whitney U test for continuous variables, and \( \chi^2 \) test or Fisher’s exact test for categorical variables.

\( p \) value: Compare the patients with and without ascending aorta dilatation.

LVEDD: left ventricular end diastolic diameter, LVEF: left ventricular ejection fraction, LMR: lymphocyte-to-monocyte ratio, LDL-C: low density lipoprotein cholesterol, CRP: C-reaction protein, MPV: mean platelet volume.
post-stenotic aortic dilation, 62.3% were male patients with a median age of 60.0 (12.0) years. 41.7% of patients were cigarette smokers, 37.1% had hypertension and 9.9% were with type 2 diabetes. 52.3% of patients had tricuspid aortic valve. The median LVEF was 60.0 (7.0). The detailed information of patients with and without post-stenotic aortic dilation were summarized in the Table 1.

LMR and severe post-stenotic aortic dilation

LMR in patients with severe post-stenotic aortic dilation or not
LMR was significantly reduced in patients with severe post-stenotic aortic dilation (2.72 vs. 3.53, \( p = 0.002 < 0.05 \)) compared to patients without severe post-stenotic aortic dilation.

The correlation of LMR and maximal diameter of ascending aorta
There was an inverse correlation observed between the maximal diameter of ascending aorta and LMR in the overall patients \( (r = -0.217, p = 0.002 < 0.05) \) (Fig. 2).

Severe post-stenotic aortic dilation in the high-LMR and low-LMR groups
The cut-off LMR was determined by the diagnostic tests using the receiver operating curve (ROC) (AUC 0.640, 95% CI: [0.552–0.728], \( p = 0.002 \)). When the value of sensitivity + specificity—1 reaches the maximum, the cut-off LMR was determined, which is 2.72 (Additional file 1: Fig. S1). Accordingly, the subjects were assigned into the high-LMR \( (n = 142) \) and low-LMR group \( (n = 66) \). The detailed information of two groups was summarized in Table 2. For severe post-stenotic aortic dilation, the prevalence of high-LMR group was statistically lower than that of low-LMR group \( (19.7\% \text{ vs. } 43.9\%, \ p < 0.001) \). The maximal diameter of ascending aorta was significantly reduced in the high-LMR group \( (4.35 \text{ vs. } 4.76, \ p = 0.003 < 0.05) \) compared to low-LMR group (Fig. 3).

LMR associated with severe post-stenotic aortic dilation
Multivariable analysis of risk factors for severe post-stenotic aortic dilation was carried out by including all possible predictive variables (including age, sex, hypertension,
diabetes, smoking, LMR, left ventricular ejection fraction, neutrophil, platelet, C-reaction protein, low-density lipoprotein cholesterol and tricuspid aortic valve) [18, 19]. The results showed that LMR was associated with severe post-stenotic aortic dilation in Table 3 with a satisfied ROC curve (AUC 0.743, 95% CI: [0.573–0.964], \( p = 0.025 \)) (Additional file 1: Fig. S2).

**Discussion**

In this case–control study, 208 patients were enrolled and the correlation between LMR and severe post-stenotic aortic dilation was analyzed. The results presented the evidence of a lower LMR in the patients with severe post-stenotic aortic dilation compared to the patients without post-stenotic aortic dilation. The prevalence of severe post-stenotic aortic dilation in the high-LMR group was statistically lower than that in the low-LMR group. Finally, LMR was considered associated with severe post-stenotic aortic dilation after adjusting other possible variables.

Severe post-stenotic aortic dilation is often clinically silent until its complications, acute aortic dissection or rupture, occurs [20]. Although Davies and colleagues demonstrated that the ascending aorta with a diameter within 35–39 mm is not associated with aortic rupture or dissection, the risk of rupture or dissection increased dramatically by 27-fold if the diameter of ascending aorta reaches 60 mm or more [21]. Thus, it is a clinical priority to identify the predictive biomarkers or modifiable risk factors in the prevention and treatment of severe post-stenotic aortic dilation.

The associated risk factors for post-stenotic aortic dilation in the previous reports were mainly male gender, bicuspid aortic valve, hypertension and smoking [3, 22, 23]. Aortic dilatation has been linked with inflammatory diseases such as infectious aortitis, Takayasu arteritis, and giant cell arteritis [7, 8, 24]. While levels of several inflammatory biomarkers such as C-reactive protein (CRP) and interleukin (IL)-6 are elevated in patients with thoracic aortic aneurysms, suggesting the effects of systemic inflammation on the pathophysiology [6]. Of note, an increased activity of matrix metalloproteinases (MMPs) has been described in the media of thoracic aortic aneurysm, a characteristic of localized inflammation [9, 25]. Recent evidence from basic research has also suggested the role of several canonical inflammatory signaling pathways, AP-1 and the ERK1/2 signaling pathway, in contributing to the inflammation...
### Table 2  Clinical characteristics of patients with high-LMR or low-LMR

|                        | High-LMR | Low-LMR | \(p\) value |
|------------------------|----------|---------|-------------|
| Patient population (n) | 142      | 66      |             |
| Demographic data       |          |         |             |
| Age (years)            | 59 (13)  | 63 (8.25)| 0.005       |
| Sex, male (n)          | 86 (60.6%) | 49 (74.2%) | 0.048       |
| Medical history        |          |         |             |
| Hypertension (n)       | 42 (29.6%)| 33 (50.0%) | 0.004       |
| Smoking (n)            | 62 (43.7%)| 32 (48.5%) | 0.488       |
| Diabetes (n)           | 14 (9.9%) | 4 (6.1%) | 0.372       |
| Post-calcific stenotic aortic dilatation (n) | 28 (19.7%) | 29 (43.9%) | <0.001 |
| Maximal diameter of the ascending aorta (cm) | 4.35 (1.03) | 4.76 (1.60) | 0.003       |
| Tricuspid aortic valve(n) | 61 (43.0%) | 52 (78.8%) | <0.001       |
| Baseline echocardiography |          |         |             |
| LVEDD (cm)             | 5.41 (1.43) | 6.29 (1.41) | <0.001       |
| LVEF (%)               | 60 (7)    | 58 (7.5) | 0.031       |
| Preoperative laboratory tests |          |         |             |
| Leukocyte \(10^9/L\)   | 5.74 (1.93) | 6.16 (1.90) | 0.020       |
| Neutrophil \(10^9/L\)  | 3.33 (1.48) | 3.73 (1.26) | 0.004       |
| Platelet \(10^9/L\)    | 193 (69)  | 187 (85.25) | 0.818       |
| Monocyte \(10^9/L\)    | 0.47 (0.20) | 0.79 (0.43) | <0.001       |
| Lymphocyte \(10^9/L\)  | 1.88 (0.51) | 1.54 (0.67) | <0.001       |
| LDL-C (mmol/L)         | 2.87 (1.18) | 2.68 (1.12) | 0.101       |
| CRP (mg/L)             | 0.77 (1.43) | 1.18 (2.07) | 0.134       |
| MPV (fl)               | 10.90 (1.30) | 10.60 (1.15) | 0.287       |

The categorical variables in the table are presented by the number of cases (with percentage) and the continuous variables are expressed by the median (with interquartile range) or mean (with standard deviation)

\(p\) values were the results of unpaired t-test or Mann–Whitney U test for continuous variables, and \(\chi^2\) test or Fisher’s exact test for categorical variables

\(p\) value: Compare the overall patients with Low-LMR or High-LMR

LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction, LMR lymphocyte-to-monocyte ratio, LDL-C low density lipoprotein cholesterol, CRP C-reaction protein, MPV mean platelet volume

**Fig. 3** The prevalence of severe post-stenotic aortic dilation in the high-LMR and low-LMR groups. Figure depicts the prevalence of severe post-stenotic aortic dilation in the high-LMR and low-LMR groups. LMR lymphocyte-to-monocyte ratio.
in post-stenotic aortic dilation [26]. However, the detailed mechanisms underlying the inflammatory reaction in post-stenotic aortic dilation is still unclear. And it is still currently unclear which inflammatory cell set is primarily responsible for the inflammatory reaction in post-stenotic aortic dilation. Thus, identifying feasible inflammatory biomarkers will be constructive in predicting the high-risk patients and supportive in early diagnosis and intervention.

LMR is a measure calculated from the exact number of lymphocytes and monocytes in the peripheral blood. As an inflammation-related indicator, a lower LMR appears to be associated with decreased survival and increased recurrence in malignancies [27]. LMR has recently been emphasized associated with severity of coronary artery disease and prognosis following coronary artery bypass graft and percutaneous coronary intervention [10–12]. Besides, LMR has also been linked with the severity of rheumatic mitral valve stenosis, death prediction in heart failure, and survival after endovascular repair of abdominal aortic aneurysms [13–15]. Our findings demonstrated that LMR is significantly lower in the patients with severe post-stenotic aortic dilation compared to the patients without post-stenotic aortic dilation. An inverse correlation was observed between the maximal diameter of ascending aorta and LMR. It indicated that as the maximal diameter of ascending aorta develops from the normal status to dilatation, LMR might reduce proportionally. Thus, the patients with CAVS having a lower LMR could be potentially categorized into the high-risk population of post-stenotic aortic dilation. And this parameter is potentially applied to identify the patients with mild to moderate aortic dilation, follow-up the disease progression as well as disease stratification. Due to the narrow treatment time window for aortic aneurysm and dissection, early diagnosis and prognostic assessment is essential. Early recognition of patients in higher risk of post-stenotic aortic dilation would allow medical staffs to take timely measures to prevent the occurrence of aortic dissection and even rupture. With the aid of risk stratification of post-stenotic aortic dilation by LMR, early identification of patients at high risk might be realized, which would lead to the close monitoring and early initiation of efficient preventive and therapeutic strategies. Besides, a fraction of patients with post-stenotic aortic dilation is asymptomatic until aortic dissection or rupture occurs. For this group of patients, aortic CTA is not often included in routine physical examination and follow-up. Therefore, LMR might be easier and cheaper for follow-up of these patients. A more accurate cut-off LMR should be confirmed by more prospective studies with larger sample sizes, in order to aid in risk-stratification in the future.

### Limitations

Several limitations were present and special attention should be paid to interpret the results in this study. First of all, the study design, a single-center retrospective observational study, inevitably introduced a source of potential bias. The second limitation lies in a small sample size. Third, some confounding variables, such as other inflammatory markers, might influence the role of LMR in post-stenotic aortic dilation. Fourth, the association of LMR and mid- and long-term endpoints was not investigated. Fifth, the case–control design of this study did not evaluate the causal relationships between LMR and post-stenotic aortic dilation. Sixth, the exclusion criteria restricted the selection of population and excluded the patients with other common cardiovascular conditions to isolate an effect of LMR on outcomes. It might make the results only applicable in some clinical settings.

### Conclusions

LMR is inversely correlated with the prevalence and severity of post-stenotic aortic dilation and might be associated with post-stenotic aortic dilation. Further large-scale case–control studies are needed to confirm these results in the future.

### Abbreviations

CAVS: Calcific aortic valve stenosis; BAV: Bicuspid aortic valve; TAV: Tricuspid aortic valve; LMR: Lymphocyte-to-monocyte ratio; GCP: Good clinical practice; ACC: American College of Cardiology; AHA: American Heart Association; TTE: Transthoracic echocardiography; CTA: CT angiography; SD: Standard deviation; ROC: Receiver operating curve; CRP: C-reactive protein; MMPs: Matrix metalloproteinases.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02636-3.

**Table 3** Multivariate analysis of risk factors for severe post-stenotic aortic dilation

| Variables | B    | SE   | p value | OR  | 95% CI       |
|-----------|------|------|---------|-----|--------------|
| Age       | 0.057| 0.017| 0.041   | 1.059| 1.023–1.095  |
| LMR       | −0.371| 0.128| 0.004   | 0.690| 0.537–0.886  |
| Hypertension | 0.284| 0.340| 0.034   | 1.329| 1.257–1.401  |
| Constant  | 2.218| 1.183| 0.018   | 1.243|              |

Multivariate analysis of risk factors for severe post-stenotic aortic dilation were performed. p values were the results of binary logistic regression analysis. LMR lymphocyte to monocyte ratio, OR odds ratio, CI confidence interval, SE standard error.
Acknowledgements
Not applicable.

Author contributions
SC and ZW analyzed and interpreted the patient data regarding the severe post-calcific stenotic aortic dilatation. XM and YY were major contributor in writing the manuscript. All authors read and approved the final manuscript.

Funding
The current work was supported by grants from the National Nature Science Foundation of China (81800255 to MX), Natural Science Foundation of Shandong Province (ZR2018HJ002 to MX and ZR2020MH044 to ZC) and Jinan Science and Technology Plan Project (2020JN165 to ZH and MX).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Shandong Provincial Hospital affiliated to Shandong First Medical University and Shandong University and the approval code for this study was NSFC2018-002. The study was performed in accordance with the Good Clinical Practice (GCP) and principles of the Declaration of Helsinki. The Ethics Committee of Shandong Provincial Hospital affiliated to Shandong First Medical University and Shandong University approved to waive the need for written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Cardiovascular Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, No.324 Jingyu Road, Jinan 250021, Shandong, China. 2 Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324 Jingyu Road, Jinan 250021, Shandong, China. 3 Department of Radiology, Qilu Hospital of Shandong University, No. 107 West Wenhua Road, Jinan 250012, Shandong Province, China.

Received: 2 November 2021 Accepted: 15 April 2022

Published online: 26 April 2022

References
1. Lindman BR, Clavel MA, Mathieu P, Jung B, Lancellotti P, Otto CM, et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006.
2. Peeters F, Meex SJR, Dweck MR, Aikawa E, Crijns H, Schurgers LJ, et al. Calcific aortic valve stenosis: hard disease in the heart: a biomolecular approach towards diagnosis and treatment. Eur Heart J. 2018;39(28):2618–24.
3. Wilton E, Jahangiri M. Post-stenotic aortic dilatation. J Cardiothorac Surg. 2006;1:7.
4. Zhang X, Luo M, Fang K, Li J, Peng Y, Zheng L, et al. Analysis of the formation mechanism and occurrence possibility of post-stenotic dilatation of the aorta by CFD approach. Comput Methods Programs Biomed. 2020;194:105522.
5. Edlin J, Youssef P, Bilhau R, Figuerola CA, Morgan R, Nowell J, et al. Haemodynamic assessment of bicuspid aortic valve aortopathy: a systematic review of the current literature. Eur J Cardiothorac Surg. 2019;55(4):610–7.
6. Artemiou P, Chareokopis N, Rousska E, Sabol F, Chrysogonidis I, Tsavdari-dou V, et al. C-reactive protein/interleukin-6 ratio as marker of the size of the uncomplicated thoracic aortic aneurysms. Interact Cardiovasc Thorac Surg. 2012;15(3):871–7.
7. Muratore F, Salvarani C. Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab. Ann Rheum Dis. 2021;80(7):e121.
8. Nakayama M, Fuse K, Sato M, Okabe M, Misumi S, Yamashina A, et al. Infection aortitis caused by Salmonella Dublin followed by aneurysmal dilatation of the abdominal aorta. Intern Med. 2012;51(20):2099–11.
9. Shen M, Lee J, Basu R, Sakamuri SS, Wang X, Fan D, et al. Divergent roles of matrix metalloproteinase 2 in pathogenesis of thoracic aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35(4):888–96.
10. Gong S, Gao X, Xu F, Shang Z, Li S, Chen W, et al. Association of lymphocyte to monocyte ratio with severity of coronary artery disease. Medicine. 2018;97(43):e12813.
11. Murat SN, Yarlioglu M, Celik IE, Kurtal A, Duran M, Klici A, et al. The relationship between lymphocyte-to-monocyte ratio and bare-metal stent in-stent restenosis in patients with stable coronary artery disease. Clin Appl Thromb. Hemost. 2017;23(3):235–40.
12. Okuzu F, Elick D, Yarlioglu M, Duran M, Ozturk S, Celik E, et al. The relationship between lymphocyte-to-monocyte ratio and saphenous vein graft patency in patients with coronary artery bypass graft. Biomark Med. 2017;11(10):867–76.
13. Demir V, Samet Y, Akboga MK. Association of lymphocyte–monocyte ratio and monocyte-to-high-density lipoprotein ratio with the presence and severity of rheumatic mitral valve stenosis. Biomark Med. 2017;11(8):657–63.
14. Lecumberry E, Ruiz-Carmona C,Mateos E, Galarza A, Subirana I, Clara A. Prognostic value of inflammatory biomarkers in 5-year survival after endovascular repair of abdominal aortic aneurysms in a predominantly male cohort. Implications for practice World J Surg. 2021;45(6):1940–55.
15. Silva N, Bettercort P, Guimaraes JT. The lymphocyte-to-monocyte ratio: an added value for death prediction in heart failure. Nutr Metab Cardiovasc Dis. 2015;25(11):1033–40.
16. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
17. Coetzee L, Braam RA, Waalewijn RA, Schepens MA, Loeys BL, van Oostehout MF, et al. What is new in dilatation of the ascending aorta? Review of current literature and practical advice for the cardiologist. Circulation. 2011;123(8):924–8.
18. Della Corte A, Bancone C, Quarto C, Dialetto G, Covino FE, Scardone M, et al. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J Cardiothorac Surg. 2007;31(3):397–404 (discussion-5).
19. Iq็ดdar AF, D’Oulke DJ, Silverman DI, Thompson PD, D’Sicopio AW, Palac RT. Predictors of rapid aortic dilatation in adults with a bicuspid aortic valve. J Heart Valve Dis. 2011;20(3):292–8.
20. Bhave NM, Eagle KA. “Much more than a tube”: the aneurysmal ascending aorta as a dynamic entity. JACC Cardiovasc Imaging. 2019;12(6):1030–1.
21. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73(1):17–27 (discussion-8).
22. Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1991;13(3):452–8.
23. Rogers IS, Massaro JM, Trauong QA, Mahabadi AA, Kriegel MF, Fox CS, et al. Distribution, determinants, and normal reference values of thoracic and abdominal aortic diameters by computed tomography (from the Framingham Heart Study). Am J Cardiol. 2013;111(10):1510–6.
24. Jud P, Verheyen N, Dejaeco C, Haas E, Sotlar D, Mehniter A, et al. Prevalence and prognostic factors for aortic dilatation in giant cell arteritis—a longitudinal study. Semin Arthritis Rheum. 2021;51(4):911–8.
25. Li T, Jiang B, Li X, Sun HY, Li XT, Jing JJ, et al. Serum matrix metalloproteinase-9 is a valuable biomarker for identification of abdominal and thoracic aortic aneurysm: a case–control study. BMC Cardiovasc Disord. 2018;18(1):202.
26. Tobin SW, Alibhai FJ, Lee MM, Yeganeh A, Wu J, Li SH, et al. Novel mediators of aneurysm progression in bicuspid aortic valve disease. J Mol Cell Cardiol. 2019;127:71–83.
27. Dupre A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol. 2018;44(5):566–70.